Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Below 50-Day Moving Average of $8.27

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $8.27 and traded as low as $7.55. Voyager Therapeutics shares last traded at $7.59, with a volume of 359,068 shares.

Analyst Ratings Changes

A number of equities research analysts have weighed in on VYGR shares. Oppenheimer reiterated an “outperform” rating and set a $18.00 price target on shares of Voyager Therapeutics in a research note on Wednesday, May 15th. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Guggenheim began coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, May 16th. Finally, Citigroup started coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They set a “buy” rating and a $16.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Voyager Therapeutics Stock Down 3.4 %

The stock has a 50 day simple moving average of $8.27 and a 200 day simple moving average of $8.39. The stock has a market cap of $412.82 million, a price-to-earnings ratio of -151.77 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.24. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The business had revenue of $19.52 million for the quarter, compared to analysts’ expectations of $10.33 million. Equities analysts expect that Voyager Therapeutics, Inc. will post -1.39 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VYGR. Ameritas Investment Partners Inc. increased its position in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after purchasing an additional 1,300 shares during the last quarter. SummerHaven Investment Management LLC lifted its holdings in Voyager Therapeutics by 1.9% in the 4th quarter. SummerHaven Investment Management LLC now owns 74,146 shares of the company’s stock worth $626,000 after buying an additional 1,367 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Voyager Therapeutics by 2.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after buying an additional 2,030 shares during the period. Ritholtz Wealth Management lifted its stake in shares of Voyager Therapeutics by 11.8% in the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after purchasing an additional 2,089 shares during the period. Finally, Empowered Funds LLC lifted its stake in shares of Voyager Therapeutics by 8.2% in the 1st quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock valued at $367,000 after purchasing an additional 2,975 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.